Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2016
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Acronyms PLUMMB
- 10 Jun 2017 Biomarkers information updated
- 13 Jun 2016 Planned End Date changed from 1 Feb 2019 to 1 Jun 2019.
- 13 Jun 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Jun 2019.